Positives

• An idiopathic MCAS patient on low-dose omalizumab maintained sustained clinical response for five years and was able to safely resume bee venom immunotherapy PMC.
  
  
• In a systematic review of refractory MCAS, 78% of patients achieved at least a partial response on omalizumab, with notable improvement in vasomotor symptoms and recurrent anaphylaxis PubMed.
  
  

Negatives

• A parent of a teenager on Xolair injections reported their daughter with MCAS progressively worsened, prompting her immunologist to question whether the drug was driving the deterioration Inspire.
  
  
• A patient with MCAS-related adrenal insufficiency developed a serum sickness reaction to omalizumab, leading clinicians to flag adrenal insufficiency as a contraindication PMC.
  
  

Hurdles & Side Effects

• Patients note Xolair is off-label for MCAS, so even at the lower 150 mg monthly dose recommended for cost benefit, insurance coverage is often denied without specialist letters PMC.
  
  
• A patient who had bone pain resolve in the first four injections developed severe leg pain afterward, illustrating that response can shift unpredictably during long-term therapy Inspire.